Our Senior Medical Oncologist, Dr Tan Chee Seng was the speaker for a webinar on “Immunotherapy Approaches: A New Age in unresectable stage III Non-Small-Cell Lung Carcinoma (NSCLC)” on 11 Jun 2020.

He presented the latest clinical data on the role of consolidation immunotherapy for stage III NSCLC. Role of immunotherapy in this setting was recently approved by FDA and he shared his clinical experience with the regional audience. This was a well-received interactive webinar attended by healthcare professionals in the region.